p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease.
Curr Opin Investig Drugs
; 4(9): 1059-64, 2003 Sep.
Article
in En
| MEDLINE
| ID: mdl-14582449
ABSTRACT
p38 Mitogen-activated protein kinase (MAPK) has been implicated in cardiovascular disease and is activated by various factors, including neurohormones (e.g., catecholamines, angiotensin II and endothelin), hypoxia and wall stress. Activation of p38 MAPK can cause cardiac hypertrophy, negative inotropy and endothelial dysfunction. All of these conditions lead to chronic cardiovascular disease, which is becoming an ever growing burden on society. p38 MAPK inhibition may therefore be an interesting therapeutic approach to the treatment of various cardiovascular diseases. However, in vitro and in vivo results are conflicting and caution must be applied in the translation of bench results to the clinic.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Mitogen-Activated Protein Kinases
/
Enzyme Inhibitors
Limits:
Animals
/
Humans
Language:
En
Journal:
Curr Opin Investig Drugs
Journal subject:
TERAPIA POR MEDICAMENTOS
Year:
2003
Type:
Article
Affiliation country:
Germany